β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors

You,Chengcheng; Zhang,Shimin; Sun,Yingming; Zhang,Shiyu; Tang,Guiliang; Tang,Fang; Liu,Xuefeng; Xiao,Yu; Zhang,Junhong; Gong,Yan; Xie,Conghua

doi:10.3892/ijo.2018.4529

β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors

Authors:
- Chengcheng You
- Shimin Zhang
- Yingming Sun
- Shiyu Zhang
- Guiliang Tang
- Fang Tang
- Xuefeng Liu
- Yu Xiao
- Junhong Zhang
- Yan Gong
- Conghua Xie
View Affiliations

Affiliations: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430070, P.R. China, Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, USA, Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430070, P.R. China, Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430070, P.R. China
Published online on: August 21, 2018 https://doi.org/10.3892/ijo.2018.4529
Pages: 2258-2268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) exhibits antitumor activity in various types of tumor cell and tumor‑bearing animals. However, acquired TRAIL resistance is a common issue that restricts its clinical application. Previous studies have revealed that β‑catenin is associated with TRAIL resistance in melanoma and colorectal tumors. In the present study, an acquired‑resistance non‑small‑cell lung cancer (NSCLC) cell line (H460‑TR) was established from parental TRAIL‑sensitive H460 cells using a gradient ascent model (8‑256 ng/ml TRAIL). Cellular FADD‑like interleukin‑1β converting enzyme inhibitory protein and Mcl‑1 were upregulated and the cell surface distribution of death receptor (DR)4 and DR5 was downregulated in H460‑TR cells compared with the parental H460 cells. The results of reverse transcription‑quantitative polymerase chain reaction and western blot analysis indicated that H460 cells expressed increased levels of β‑catenin and were more sensitive to TRAIL compared with H460‑TR cells. β‑catenin‑knockdown in H460 cells decreased their sensitivity to TRAIL, while upregulation of β‑catenin expression in H460‑TR cells increased their sensitivity to TRAIL, increased the cell surface distribution of DRs and activated caspase‑3/8. Taken together, the results of the present study suggest that β‑catenin impairs acquired TRAIL resistance in NSCLC cells by promoting the redistribution of DR4 and DR5 to the cytomembrane, and inducing TRAIL‑mediated cell apoptosis via caspase‑3/8 activation.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Cao C, D’Amico T, Demmy T, Dunning J, Gossot D, Hansen H, He J, Jheon S, Petersen RH, Sihoe A, et al International VATS Interest Group: Surgery versus SABR for resectable non-small-cell lung cancer. Lancet Oncol. 16:e370–e371. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
4	Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL and Kneteman NM: TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64:8502–8506. 2004. View Article : Google Scholar : PubMed/NCBI
5	Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
6	Ashkenazi A: Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 7:1001–1012. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, et al: A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res. 14:3450–3455. 2008. View Article : Google Scholar : PubMed/NCBI
8	Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, et al: Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol. 30:4141–4147. 2012. View Article : Google Scholar : PubMed/NCBI
9	Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G and Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 61:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safty and antitumor activity of recombinant soluble Apo 2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
11	Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH and Petruk KC: Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 61:1162–1170. 2001.PubMed/NCBI
12	Jalving M, Heijink DM, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, Sluiter WJ, de Vries EG, Kleibeuker JH and de Jong S: Regulation of TRAIL receptor expression by β-catenin in colorectal tumours. Carcinogenesis. 35:1092–1099. 2014. View Article : Google Scholar : PubMed/NCBI
13	Lu M, Marsters S, Ye X, Luis E, Gonzalez L and Ashkenazi A: E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol Cell. 54:987–998. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yang B, Zhang S, Wang Z, Yang C, Ouyang W, Zhou F, Zhou Y and Xie C: Deubiquitinase USP9X deubiquitinates β-catenin and promotes high grade glioma cell growth. Oncotarget. 7:79515–79525. 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S and Belka C: Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene. 24:130–140. 2005. View Article : Google Scholar
17	Ozören N and El-Deiry WS: Defining characteristics of types I and II apoptotic cells in response to TRAIL. Neoplasia. 4:551–557. 2002. View Article : Google Scholar : PubMed/NCBI
18	de Miguel D, Lemke J, Anel A, Walczak H and Martinez-Lostao L: Onto better TRAILs for cancer treatment. Cell Death Differ. 23:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
19	Teng Y, Gao M, Wang J, Kong Q, Hua H, Luo T and Jiang Y: Inhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. Cell Death Dis. 5:e10602014. View Article : Google Scholar
20	Fan S, Li Y, Yue P, Khuri FR and Sun SY: The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia. 12:346–356. 2010. View Article : Google Scholar : PubMed/NCBI
21	Haimovici A, Humbert M, Federzoni EA, Shan-Krauer D, Brunner T, Frese S, Kaufmann T, Torbett BE and Tschan MP: PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression. Cell Death Differ. 24:866–877. 2017. View Article : Google Scholar : PubMed/NCBI
22	Mert U and Sanlioglu AD: Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. Cell Mol Life Sci. 74:245–255. 2017. View Article : Google Scholar
23	Safa AR and Pollok KE: Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel). 3:1639–1671. 2011. View Article : Google Scholar
24	Chen F, Guo J, Zhang Y, Zhao Y, Zhou N, Liu S, Liu Y and Zheng D: Knockdown of c-FLIP(L) enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells. Cancer Sci. 100:940–947. 2009. View Article : Google Scholar : PubMed/NCBI
25	Jeon MY, Min KJ, Woo SM, Seo SU, Kim S, Park JW and Kwon TK: Volasertib enhances sensitivity to TRAIL in renal carcinoma Caki cells through downregulation of c-FLIP expression. Int J Mol Sci. 18:1–12. 2017. View Article : Google Scholar
26	Murphy ÁC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, Loh KP, Kögel D, Letai AG, Prehn JH and Murphy BM: Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis. 19:629–642. 2014. View Article : Google Scholar :
27	Azijli K1, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S and Kruyt FA: MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis. 18:851–860. 2013. View Article : Google Scholar : PubMed/NCBI
28	Woo SM, Min KJ, Seo BR and Kwon TK: YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells. Oncotarget. 7:61520–61532. 2016. View Article : Google Scholar : PubMed/NCBI
29	Jin Z, McDonald ER III, Dicker DT and El-Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 279:35829–35839. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ouyang W, Yang C, Zhang S, Liu Y, Yang B, Zhang J, Zhou F, Zhou Y and Xie C: Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells. Int J Oncol. 42:699–711. 2013. View Article : Google Scholar
31	Inamura K: Lung Cancer: Understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 7:1932017. View Article : Google Scholar : PubMed/NCBI
32	Polakis P: Drugging Wnt signalling in cancer. EMBO J. 31:2737–2746. 2012. View Article : Google Scholar : PubMed/NCBI
33	Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012. View Article : Google Scholar : PubMed/NCBI
34	Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT and Chien AJ: Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One. 8:e695932013. View Article : Google Scholar
35	Lan Y, Liu X, Zhang R, Wang K, Wang Y and Hua ZC: Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. Biometals. 26:241–254. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, Lynch PM, Moyer MP, Wen XF and Wu X: Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 464:1058–1061. 2010. View Article : Google Scholar : PubMed/NCBI
37	Wu X, Deng G, Hao X, Li Y, Zeng J, Ma C, He Y, Liu X and Wang Y: A caspase-dependent pathway is involved in Wnt/β-catenin signaling promoted apoptosis in Bacillus Calmette-Guerin infected RAW264.7 macrophages. Int J Mol Sci. 15:5045–5062. 2014. View Article : Google Scholar : PubMed/NCBI
38	Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze’ev A, Pestell RG and Lisanti MP: Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem. 275:23368–23377. 2000. View Article : Google Scholar : PubMed/NCBI
39	Gajate C and Mollinedo F: Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem. 280:11641–11647. 2005. View Article : Google Scholar : PubMed/NCBI
40	Brozovic A: The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 91:605–619. 2017. View Article : Google Scholar